Loading…
← CockpitCompetitor Analysis › 301408.SZ Anhui Huaren Health Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Anhui Huaren Health Pharmaceutical Co., Ltd. Class A301408.SZCompetitor analysis, valuation and peers

China · CNY·Consumer Staples›Drugstore Chains
Momentum weak 29
Mkt cap
$745M
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$21.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+8.7 pp
WACC 6.1%
Hurdle
-31 pp
Req g minus delivered
Close · CNYCN¥12.59
1D-1.3%
1W-11.5%
1M-10.5%
3M-25.2%
6M-31.9%
YTD-32.2%
1Y-8.0%
ATR %4.6%
52w lowhigh57.7% off high

What Anhui Huaren Health Pharmaceutical does

Employees: 8,938

Anhui Huaren Health Pharmaceutical at a glance

Size Anhui Huaren Health Pharmaceutical (301408.SZ) is a China Consumer Staples company (Drugstore Chains) with a market value of $745M, the 2748th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.59 on 18 Nov 2026.

Performance Over six months the shares fell 31.9%, against -4.5% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 15 in its peer set.

Growth Revenue grew 14.6% over the last twelve months (peer median +3.9%); the operating margin is 8.0% (peer median 3.8%).

Valuation It trades at 1.1× enterprise value to sales against a peer median of 0.7× (4th most expensive of 15).

Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -31 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 8.7 points above its cost of capital (6.1% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 95301408.SZ 67
Six months, rebased to 100: Anhui Huaren Health Pharmaceutical against the median of its 14 peers (local-currency closes).

Anhui Huaren Health Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥5.91BCN¥5.47BCN¥4.52BCN¥3.80BCN¥3.25B
Revenue growth—+21%+19%+17%—
Gross profitCN¥2.29BCN¥1.79BCN¥1.41BCN¥1.12BCN¥980M
EBITDAn/aCN¥742MCN¥538MCN¥388MCN¥439M
Net incomeCN¥250MCN¥191MCN¥138MCN¥115MCN¥161M
Free cash flowCN¥756MCN¥689MCN¥412M-CN¥83.8MCN¥69.5M
Capital expenditureCN¥135MCN¥153MCN¥161MCN¥216MCN¥105M
Total debtCN¥2.99BCN¥2.59BCN¥2.06BCN¥2.06BCN¥1.24B

Quarterly statements and history in the cockpit →

Anhui Huaren Health Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%9267MEDPLUS301017266430346035900027880027279627000504603883600833605266301408.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Anhui Huaren Health Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%0×2×4×9267MEDPLUS30101726643034603590000504600833301408.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Anhui Huaren Health Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%0%20%MEDPLUS3010172664303460359000278800272796273148603883600833605266301408.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Anhui Huaren Health Pharmaceutical is the large dot.

Anhui Huaren Health Pharmaceutical competitors and peer comparison

How Anhui Huaren Health Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Anhui Huaren Health Pharmaceutical against its 14 peers (data as of 18 Nov 2026)
Measure301408.SZPeer medianRank in peer set
1-month return-10.5%-1.0%6th lowest of 15
6-month return-31.9%-4.5%5th lowest of 15
Distance from 52-week high-57.7%-35.5%2nd lowest of 15
Revenue growth (TTM)+14.6%+3.9%4th highest of 15
Operating margin8.0%3.8%2nd highest of 15
EV / Sales1.1×0.7×4th most expensive of 15
Growth the price implies (Req g, 7 yrs)-7.5%-6.3%6th least demanding of 13
Growth delivered (Del g)+23.3%+8.9%highest of 13
Hurdle (Req g minus delivered)-30.8 pp-17.9 ppleast demanding of 13
ROIC minus cost of capital+8.7 pp+1.8 pp2nd highest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Anhui Huaren Health Pharmaceutical 301408.SZChina$745M-32%+15%8%1.1×-7.5%+23.3%
Genky DrugStores 9267.TJapan$728M+3%+8%5%0.6×n/an/a
MedPlus Health Services MEDPLUS.NSIndia$771M-36%+21%4%1.1×18.6%+17.6%
Shu Yu Civilian Pharmacy 301017.SZChina$701M-11%+9%2%0.8×1.1%+17.4%
Cawachi 2664.TJapan$562M+31%-1%2%0.2×-6.1%0.0%
Qol 3034.TJapan$561M+26%+5%6%0.4×-16.6%+12.4%
Beijing Konruns Pharmaceutical 603590.SSChina$558M-33%-1%17%4.2×12.4%+2.7%
Luyan Pharma 002788.SZChina$514M-32%+3%3%0.4×-0.4%+6.5%
Yixintang Pharmaceutical 002727.SZChina$1.16B+4%-2%3%0.5×-16.0%+6.5%
Ain 9627.TJapan$1.25B+2%+42%4%0.5×-6.5%+16.9%
Create SD 3148.TJapan$1.32B+3%+9%5%0.3×-11.5%+8.0%
Landfar Bio-medicine 000504.SZChina$351M-22%+497%-2%3.1×n/an/a
LBX Pharmacy Chain Joint Stock 603883.SSChina$1.71B+13%+3%5%0.8×-10.7%+9.7%
Shanghai No. 1 Pharmacy 600833.SSChina$299M-22%+1%-1%0.9×19.5%+6.1%
JZJ Chain Drugstore Corporation 605266.SSChina$293M-35%-5%0%0.7×-9.9%+14.8%

Questions

Which companies are Anhui Huaren Health Pharmaceutical's closest peers?
The cockpit's peer set: Genky DrugStores (9267.T), MedPlus Health Services (MEDPLUS.NS), Shu Yu Civilian Pharmacy (301017.SZ), Cawachi (2664.T), Qol (3034.T), Beijing Konruns Pharmaceutical (603590.SS), Luyan Pharma (002788.SZ), Yixintang Pharmaceutical (002727.SZ).
Is Anhui Huaren Health Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 1.1× against a peer median of 0.7×, 4th most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -31 pp: the price already allows for a slowdown.
How has Anhui Huaren Health Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -31.9% against -4.5% for the median peer; over one year -8.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.